ObamaCare’s affect on Biomedical Research
A piece in The Scientist briefly highlights some of the consequences of the Court’s upholding of the Affordable Care Act a.k.a. ObamaCare.
The key provisions that have a bearing on the lives and work of biomedical researchers include the establishment of a streamlined US Food and Drug Administration pathway for the approval of generic versions of protein-based drugs, so-called biosimilars; the creation of a translational research initiative at the National Institutes of Health called the Cures Acceleration Network; the launch of the Physician Payment Sunshine Act, which would require pharmaceutical and device makers to disclose all payments greater than $10 to physicians, and a push to increase funding for comparative effectiveness research.
How this will play out in effective legislature the next several months will tell us.